Pfizer (PFE) Current Deferred Revenue (2020 - 2025)

Pfizer (PFE) has reported Current Deferred Revenue for 6 consecutive years, with $784.0 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Current Deferred Revenue fell 48.11% year-over-year to $784.0 million in Q4 2025; TTM through Dec 2025 was $784.0 million, a 48.11% decrease from a year earlier, with the FY2025 full-year figure at $784.0 million, down 48.11% from the prior year.
• Current Deferred Revenue was $784.0 million for Q4 2025 at Pfizer, down from $924.0 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $4.3 billion in Q3 2021 and troughed at $784.0 million in Q4 2025.
• A 5-year average of $2.3 billion and a median of $2.3 billion in 2021 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue jumped 175.56% in 2021 and plunged 66.19% in 2023, its largest moves.
• Over 5 years, Current Deferred Revenue stood at $3.1 billion in 2021, then retreated by 17.84% to $2.5 billion in 2022, then climbed by 7.14% to $2.7 billion in 2023, then plunged by 44.04% to $1.5 billion in 2024, then slumped by 48.11% to $784.0 million in 2025.
• The last three Current Deferred Revenue figures came in at $784.0 million (Q4 2025), $924.0 million (Q3 2025), and $1.1 billion (Q2 2025), per Business Quant data.